氢吗啡酮微创给药泵临床应用及稳定性研究进展  

Clinical application and stability of hydromorphone in an implantable imfusion system:research advances

作　　者：梁平[1] 史学莲[2] 候娟[1] 李芮琳 宛春甫[2] 杜丽英[1] 刘明峰[1] 刘江[1] 

机构地区：[1]河北医科大学第四医院药学部,石家庄050011 [2]河北医科大学第四医院疼痛科,石家庄050011

出　　处：《国际药学研究杂志》2017年第3期240-244,共5页Journal of International Pharmaceutical Research

基　　金：河北省卫生厅科研项目(20150368)

摘　　要：2013年在中国新上市的氢吗啡酮是一种作用强于吗啡的阿片类镇痛药,可用于中至重度疼痛。微创给药包括持续输注及自控镇痛(PCA),并且其中PCA具有起效快、可及时控制爆发痛、患者满意度高等优势,目前被广泛应用于急、慢性疼痛和癌性疼痛的治疗。但是,随之也带来一些涉及用药安全的思考,如药物配伍后注药泵内药物的稳定性问题不容忽视。本文将近几年氢吗啡酮在不同镇痛泵中的临床应用以及稳定性(外观、p H值和浓度的变化情况)等进行归纳总结,为临床合理应用氢吗啡酮提供依据。Hydromorphone（HM）,appeared in the Chinese market in 2013 is a more potent opioid analgesic than morphine and is used for moderate to severe pain. Micro-invasive drug administration methods,including continuous infusion and patientcon？trolled analgesia（PCA）,will provide hopes for controlling the outbreak of pain and improving patients＇ satisfaction. At present ,hydro？morphone is the most commonly used drug for the treatment of acute pain,chronic pain and cancer pain. However,we should also con？sider the stability and compatibility of hydromorphone in the implantable infusion system that is most commonly used in these patients. The purpose of this paper is to review the clinical application and stability（changes in color,pH and concentration）of hydromor？phone in different infusion systems so as to provide the basis of rational clinical application.

关 键 词：氢吗啡酮 微创 自控镇痛 自控镇痛泵 稳定性 

分 类 号：R971[医药卫生—药品]